EQS-Adhoc : Achiko AG: Achiko completes initial shipment of AptameX, its progressive Covid-19 diagnostic test, to Indonesia, delivering 77% sensitivity at low viral loads

EQS Group-Ad-hoc: Achiko AG / Key word(s): Preliminary Results 
Achiko AG: Achiko completes initial shipment of AptameX, its progressive Covid-19 diagnostic test, to Indonesia, 
delivering 77% sensitivity at low viral loads 
20-May-2021 / 06:45 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Achiko completes initial shipment of AptameX, its progressive Covid-19 diagnostic test, to Indonesia, delivering 77% 
sensitivity at low viral loads 
- Production of first 1,000 AptameX test kits is concluded in Singapore (initial capacity to test 10,000 patients per 
day). 
- AptameX delivers sensitivity of 77% (95% CI: 75.94 - 79.24) at a high industry CT score of 28.3, which is comparable 
to current lateral flow rapid tests. 
- Moving to complete product registration in Indonesia and progressing to securing a CE mark in Europe with a view to 
approvals and sales in Q3 2021. 
Zurich, 20 May 2021 - Achiko AG (SWX:ACHI, ISIN CH0522213468) completed production of the first 1,000 AptameX test kits 
and has commenced shipment to Indonesia. The Company also announces favourable preliminary Covid-19 diagnostic testing 
results at a high CT score; even at low viral loads, AptameX proves to be highly sensitive. 
Against the background of the expansion of its production capacities in Singapore, Spain, Taiwan and Indonesia, the 
distribution of the test kits represents an important milestone for the Company, made possible after AptameX recently 
received a distribution certificate via Achiko's joint venture partner PT Indonesia Farma Medis ("IFM") in Indonesia. 
The Company is progressing forward with product registration and final validation trials, ensuring full test kit 
availability in early Q3 2021. Achiko's and IFM's joint venture company PT Achiko Medis Indonesia will undertake the 
initial rollout of AptameX and the mobile app Teman Sehat in Indonesia. Achiko earns a profit share relative to its 50% 
holding and a 10% licensing fee from gross sales. 
"In geographies with little vaccination coverage, an ultra low cost, accurate testing service is crucial to both ensure 
safety and restore confidence in workplaces and public spaces amongst consumers, tourists and within manufacturing," 
said Steven Goh, Chief Executive Officer of Achiko. "We believe that working together with our partners, reaching just 
2% of Indonesia's population of 270 million may be possible later this year. At 3-5 tests per person per month, that 
potentially equates to 15-25 million tests per month in Indonesia alone, producing an initial revenue stream of USD 30 
- USD 50 million a month." 
In addition, Achiko reports that the testing of AptameX achieved 77% sensitivity (95% Confidence Interval (CI): 75.94 - 
79.24) at a favourable CT score of 28.3, from both in-vitro tests in Spain and the subsequent Indonesian field testing 
of proprietory AptameX chemistry. These tests were conducted in a 96-well plate format and run against RT-PCR. 
Scientifically, a CT value signals the number of cycles for a sample to go through to amplify and bring up the viral 
DNA to a traceable level. Consequently, the higher the CT score, the lower the viral load that can be detected. 
Currently, used CT score categories are low (<18.5), meaning the viral load in a sample is high, normal (18.5-25) and 
high (>25), meaning the viral load in a sample is low. It is encouraging that Achiko's result of 77% sensitivity at a 
CT score of 28.3 is comparable to all lateral flow testing kits already in the market. The Company expects to announce 
further improvement on these numbers by a factor of at least 10% and at much higher CT scores.^[i] 
This breakthrough now sees Achiko undertaking selectivity and stability studies in Europe as a precursor to seeking 
full CE mark registration in Q3 2021. Following the CE mark registration, Achiko will respond to commercialisation 
interest across Europe, Asia, the Middle East, Africa and the Americas. 
These achievements for Achiko underscore the Company's commitment to developing a rapid, accurate and cost-effective 
solution to diagnose those with Covid-19. The investments Achiko has made in transitioning from a fintech to a 
healthtech diagnostic company are beginning to show promise; the technologies of AptameX and Teman Sehat offer an 
extraordinary solution to managing further outbreaks of Covid-19 and other diseases in the future. Achiko can respond 
and act swiftly to global public health crises, not least in developing countries. 
"I'm confident Achiko will shortly achieve its goal to deliver a diagnostic test that is available to the entire global 
population," stated Mr Goh. "The road of transforming the Company to a healthtech entity has not been without its 
challenges, however, we are now encouraged and excited by the results and our recent pace of execution." 
Achiko has now shipped the product, and is in the process of obtaining regulatory approval in its initial target market 
of Indonesia and subject to that approval, the Company will be releasing it to market in Q3 2021. Achiko has invested 
millions in developing technologies for an accurate diagnostic that will dramatically shorten the time it takes to test 
and detect Covid-19, and not least at a fraction of the price of current solutions. The Company remains absolutely 
committed to delivering a product that stands up to the rigours of scrutiny and WHO standards. 
Achiko will reinvest revenues in technologies developed as complements that enhance and expedite the safe and effective 
diagnosis of Covid-19, whilst working hand in hand with vaccine production and roll out. At the current rate of 
production, vaccination coverage extends to approximately 7% of the globe; which is significantly short of herd 
immunity. 
"Our team has been working around the clock to produce a reliable diagnostic test that helps contain the spread of 
Covid-19, on order that we help improve the livelihood and socio-economic impact of populations severely hit by this 
dangerous disease," said Dr Morris S. Berrie, President of Achiko. "Overcoming some early misinterpretations, we have 
now further elucidated those data results, and we are nothing short of exhilerated about the impact we can have, not 
least in those parts of the world that are most in need. Achiko is far from a one-trick pony; and we will be enhancing 
our current technology and putting out a broader range of related diagnostics as the year progresses." 
"Biomedtech/biopharmaceutical companies are working in close collaboration with government agencies and other 
stakeholders in the quest to beat Covid-19,", Dr Berrie added. "Everyone has a unique role to play in combatting this 
pandemic and we are confident that diagnostics have a critical part to play, and that in accordance with the 'Covid-19 
Swiss Cheese model'^[ii], it is a combination of technologies, particularly together with vaccination, that will 
succeed in overcoming the virus." 
About Achiko AG 
Achiko creates and develops new innovations in healthcare technology through its biotechnology division, AptameX, and 
its sister digital mobile health technology division, Teman Sehat. The Company has created a unique telehealth 
capability that provides user-friendly diagnostic testing integrated with a digital passport solution for the 
management of Covid-19. 
AptameX comprises of DNA aptamer-based technology that is cost-effective, chemically synthesised and widely applicable 
to the evolving diagnostic field of healthcare. Together with the digital mobile health app Teman Sehat, Achiko is 
developing potential technologies that seek to deliver rapid, affordable diagnostic testing for a range of pathogenic 
diseases and therapeutic indications. The AptameX technology is licensed from Regenacellx.sl and Achiko has exclusive 
commercialisation rights. 
Headquartered in Zurich, Achiko has offices in Hong Kong, Jakarta, Seoul and Singapore. 
Further information can be found at www.achiko.com. 
If you have any questions regarding the Company, please contact us. 
Media contacts: 
ACHIKO AG 
Investor Relations 
E: [e-mail] 
Switzerland 
Marcus Balogh 
Farner Consulting Ltd. 
E: [e-mail] 
T: [phone] 
Germany and Austria 
Axel Mühlhaus / Dr Sönke Knop 
edicto GmbH 
E: [e-mail] 
T: [phone] 
Disclaimer 
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its 
business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause 
the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any 
future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is 
providing this communication as of this date and does not undertake to update any forward-looking statements contained 
herein as a result of new information, future events or otherwise. 
^[i] Guglielmi, G: Rapid Coronavirus tests: a guide for the perplexed, 202-205 Nature, Vol 590, 11 February, 2021 
Boum, Y et al: Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in 
symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study, Lancet Infect 
Dis 2021 online, March 25, 2021 
Mak, G et al: Evaluation of rapid antigen detection kit from the WHO Emergency Use List for detecting SARS-CoV-2, J. of 
Clin. Virology, 134 (2021) 104712 
Mak, G et al: Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for detection 
of SARS-CoV-2 virus, J. of Clin. Virology, 133 (2020) 104684 
^[ii] Mackay, Ian M. (2020): The Swiss Cheese Respiratory Virus Defence 
=---------------------------------------------------------------------------------------------------------------------- 
End of ad hoc announcement 

(MORE TO FOLLOW) Dow Jones Newswires

May 20, 2021 00:47 ET (04:47 GMT)